Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | GCKR | Q14397 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271123 | 0.90 | KDM1A (0.49) | KIF11KDM1AMAOBCYP11B1HDAC1 | |
| SCHEMBL27344645 | 0.86 | KIF11 (0.63) | KIF11KDM1AMAOBCYP11B1NPSR1 | |
| SCHEMBL24408833 | 0.84 | GCK (0.55) | KIF11KDM1AMAOBCYP11B1HDAC1 | |
| SCHEMBL28530523 | 0.84 | KIF11 (0.61) | KIF11KDM1AMAOBCYP11B1NPSR1 | |
| SCHEMBL29690424 | 0.84 | KIF11 (0.61) | KIF11KDM1AMAOBCYP11B1NPSR1 | |
| SCHEMBL18002181 | 0.83 | KDM1A (0.45) | KIF11KDM1AMAOBCYP11B1NPSR1 | |
| SCHEMBL4342508 | 0.82 | KIF11 (0.59) | KIF11KDM1AMAOBCYP11B1NPSR1 | |
| SCHEMBL30747787 | 0.80 | CYP11B1 (0.56) | CYP11B1ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL28682644 | 0.80 | CYP11B1 (0.56) | CYP11B1ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL18002840 | 0.79 | KIF11 (0.42) | KIF11KDM1AMAOBNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107759522-B | Carboxylic acid derivative, preparation method thereof and application thereof in medicine | 浙江海正药业股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-7989457-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; (R,S)-Methanesulfonic acid 2-(3-methyl-4'-trifluoromethyl-biphenyl-4-yl)-propyl ester | ELI LILLY AND COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | disclosed |
| EP-1758859-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005118542-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | KIF11 3238/4885KDM1A 1110/4885MAOB 2578/4885 |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | KIF11 3904/4885KDM1A 2498/4885MAOB 3179/4885 |
| US-20150094338-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | KIF11 4048/4885KDM1A 3632/4885MAOB 2356/4885 |
| US-20120165343-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | KIF11 4048/4885KDM1A 3632/4885MAOB 2356/4885 |
| US-20150266861-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | KIF11 4048/4885KDM1A 3632/4885MAOB 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.